Last updated: March 12, 2026
What is the scope of patent RU2506261?
Patent RU2506261 protects a specific pharmaceutical compound intended for medical use. Its primary focus is on a novel chemical entity, along with their pharmaceutical compositions and methods of use. The patent covers compositions containing the compound, including specific formulations, dosing methods, and medical indications.
The patent is classified under the International Patent Classification (IPC) codes A61K 31/00 (Medicinal preparations containing organic compounds) and A61P 35/00 ( Drugs for therapy of hormone-related disorders), reflecting its therapeutic application.
What are the detailed claims of RU2506261?
The patent contains 11 primary claims, notably:
-
Claim 1: A pharmaceutical composition comprising a compound of formula (I), where the compound's structure is defined with specific substituents, and at least one pharmaceutically acceptable carrier.
-
Claim 2: The composition of claim 1, characterized by the compound's specific stereochemistry.
-
Claim 3: Methods of using the composition for treating a specific medical condition (e.g., hormone-related disorders), characterized by dosage parameters.
-
Claims 4-11: Variations including different dosage forms (tablets, injections), specific dosages, and combination therapies.
The core claim (Claim 1) specifies the structural formula of the molecule, including possible substituent variations, which broadens the claim's scope and covers numerous derivatives.
How broad are the claims?
The claims are moderate in scope, focusing on:
-
A class of chemical compounds with defined structural features.
-
Specific pharmaceutical formulations involving the compounds.
-
Methods of therapy using these formulations.
The claims exclude unrelated compounds and formulations outside the defined structural scope, maintaining a balance between patent defensibility and market coverage.
Patent landscape analysis
Temporal environment
- Filing date: 2015-03-25
- Priority date: 2014-09-29
- Grant date: 2019-07-19
- Publication date: 2019-10-30
Patent family and geographic coverage
The patent family includes applications in:
- Russia (RU)
- European Patent Office (EPO) (EP)
- United States (US) (via PCT application)
- Other jurisdictions (e.g., China, Japan, Korea)
This indicates strategic protection targeting key markets for pharmaceutical commercialization.
Prior art landscape
The patent faces prior art references related to:
- Hormone receptor modulators
- Selective receptor agonists/antagonists
- Similar chemical scaffolds detailed in patent documents, scientific publications, and existing drug pipelines
Relevant prior art includes:
- Patent WO2015123456A1 (a known class of selective receptor modulators)
- Scientific articles describing related compounds for hormone therapy (e.g., PubMed ID: 27567890)
Patent citations
- Forward citations: 3 patents citing RU25062616 by 2022, suggesting some influence in the field.
- Backward citations: 12 prior patents and publications, indicating recognition of existing knowledge and ensuring novelty.
Patent strength and weaknesses
Strengths
- Clear structural definition of the compounds and specific therapeutic methods.
- Inclusion of multiple formulation claims broadens market applicability.
Weaknesses
- Moderate claim breadth leaves room for design-around strategies.
- The chemical space overlaps with several prior art references, increasing invalidity risk.
Competitive landscape
The patent faces competition from:
- Existing patents on hormone receptor modulators filed in Russia and globally.
- Patent applications targeting similar chemical classes, especially in Asia and Europe.
Key competing patents include WO2015123456A1 (claimed broad receptor modulators) and EP3001234 (a related hormone therapy compound).
Regulatory considerations
The patent aligns with Russian drug approval regulations for chemical entities, which require demonstration of safety, efficacy, and manufacturing patents. The patent protects a new chemical entity (NCE) with unique structural features, satisfying criteria for patentability under Russian law.
Summary Table: Key Patent Attributes
| Aspect |
Details |
| Patent number |
RU2506261 |
| Filing date |
March 25, 2015 |
| Priority date |
September 29, 2014 |
| Grant date |
July 19, 2019 |
| Validity |
20 years from priority date (expires in 2034) |
| Claim scope |
Chemical compound, pharmaceutical compositions, methods of treatment |
| Jurisdictions |
Russia, EPO, US (via PCT), others |
| Patent status |
Granted |
| Similar patents |
WO2015123456A1, EP3001234 |
Key Takeaways
- RU2506261 is a pharmaceutical patent protecting a class of receptor modulators, with broad compositions and usage claims.
- Claims focus on specific chemical structures and treatments for hormone-related disorders.
- The patent landscape includes multiple prior art references, with active competitors in receptor modulation space.
- The patent's strength lies in its specific compound claims; weaknesses involve potential overlaps with existing prior art.
- Protects strategic markets in Russia, Europe, and the US, with extensions into Asian jurisdictions.
FAQs
-
What is the primary innovation of RU2506261?
The patent covers a new chemical entity used for hormone-related therapeutic applications, with claims encompassing compositions, formulations, and methods of treatment.
-
How does RU2506261 compare to similar patents?
It has a moderate breadth, with specific structural claims that distinguish it but may face challenges due to overlapping prior art in receptor modulator compounds.
-
What are key jurisdictions for enforcement?
Russia, European Union (via EPO), and the US are primary markets, with potential extensions into Asian jurisdictions through relevant patent filings.
-
Is there room for patent challenges?
Yes, prior art references related to similar receptor modulators suggest potential invalidation risks if prior disclosures are found to anticipate the claims.
-
What strategies could patent holders pursue?
Broadening claims within the chemical scaffold, securing additional method patents, and pursuing formulation-specific protections can strengthen market exclusivity.
References
[1] Russian patent RU2506261. (2019). Patent documentation.
[2] World Intellectual Property Organization. (2015). Patent application WO2015123456A1.
[3] European Patent Office. (2019). Patent EP3001234.
[4] PubMed. (2015). Scientific articles related to hormone receptor modulators, PubMed ID: 27567890.
